

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2696)

INSIDE INFORMATION ANNOUNCEMENT POSITIVE PROFIT ALERT

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary assessment of the Group’s unaudited consolidated management accounts for the year ended 31 December 2023 (the “**Reporting Period**”) and the information currently available, it is expected that the Group will record a profit for the year of no less than RMB500 million for the Reporting Period, as compared to the loss of approximately RMB695 million for the year ended 31 December 2022. This is the first time for the Group to achieve full-year profits following the Group’s achievement of its first half-year profits for the six months ended 30 June 2023.

The first time for the Group to achieve full-year profits during the Reporting Period is mainly attributable to:

- HANQUYOU, the core product of the Group, in respect which the number of patients has continued to grow, and the profitability of HANQUYOU has been enhanced during the Reporting Period.
- HANSIZHUANG, the innovative product of the Group, in respect which the sales revenue has continued to increase since its approval for marketing in March 2022.
- The Group continued to strengthen its meticulous management measures and achieved results in respect of cost control.

As the Company is still in the course of finalizing the results of the Group for the Reporting Period, the information contained in this announcement is only based on the preliminary assessment with reference to the Group's unaudited consolidated management accounts for the Reporting Period and the information currently available, which has neither been audited nor confirmed by the auditor of the Company or the audit committee of the Board. Shareholders and potential investors are advised to refer to the Group's annual results announcement for the Reporting Period which is expected to be published in March 2024.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 4 March 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.